Effects of atipamezole on selected physiologic parameters in cynomolgus macaques (Macaca fascicularis).
anesthesia
atipamezole
cynomolgus macaque
non-human primate
reversal agent
Journal
Journal of medical primatology
ISSN: 1600-0684
Titre abrégé: J Med Primatol
Pays: Denmark
ID NLM: 0320626
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
01
09
2023
accepted:
09
10
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
Atipamezole, an α-2 adrenergic receptor antagonist, reverses the α-2 agonist anesthetic effects. There is a dearth of information on the physiological effects of these drugs in cynomolgus macaques (Macaca fascicularis). We assessed atipamezole's physiologic effects. We hypothesized atipamezole administration would alter anesthetic parameters. Five cynomolgus macaques were sedated with ketamine/dexmedetomidine intramuscularly, followed 45 min later with atipamezole (0.5 mg/kg). Anesthetic parameters (heart rate, blood pressure [systolic (SAP), diastolic (DAP), and mean (MAP) blood pressure], body temperature, respiratory rate, and %SpO2) were monitored prior to and every 10 min (through 60 min) post atipamezole injection. While heart rate was significantly increased for 60 min; SAP, DAP, MAP, and temperature were significantly decreased at 10 min. This study indicates subcutaneous atipamezole results in increased heart rate and transient blood pressure decrease. These findings are clinically important to ensure anesthetist awareness to properly support and treat patients as needed.
Sections du résumé
BACKGROUND
BACKGROUND
Atipamezole, an α-2 adrenergic receptor antagonist, reverses the α-2 agonist anesthetic effects. There is a dearth of information on the physiological effects of these drugs in cynomolgus macaques (Macaca fascicularis). We assessed atipamezole's physiologic effects. We hypothesized atipamezole administration would alter anesthetic parameters.
METHODS
METHODS
Five cynomolgus macaques were sedated with ketamine/dexmedetomidine intramuscularly, followed 45 min later with atipamezole (0.5 mg/kg). Anesthetic parameters (heart rate, blood pressure [systolic (SAP), diastolic (DAP), and mean (MAP) blood pressure], body temperature, respiratory rate, and %SpO2) were monitored prior to and every 10 min (through 60 min) post atipamezole injection.
RESULTS
RESULTS
While heart rate was significantly increased for 60 min; SAP, DAP, MAP, and temperature were significantly decreased at 10 min.
CONCLUSIONS
CONCLUSIONS
This study indicates subcutaneous atipamezole results in increased heart rate and transient blood pressure decrease. These findings are clinically important to ensure anesthetist awareness to properly support and treat patients as needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Calle PP, Joslin JO. New world and old world monkeys. Fowler's Zoo and Wild Animal Medicine. Saunders. Vol 8; 2015:301-335.
Pertovaara A, Haapalinna A, Sirviö J, et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005;11(3):273-288.
Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983;35(2):143-180.
Bahri LE. Pharm profile: atipamezole. Pharmacol Compendium. 2008;30(5):256-258.
Virtanen R, Savola JM, Saano V. Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. Arch Int Pharmacodyn Ther. 1989;297:190-204.
Navarro KL, Huss M, Smith JC, Sharp P, Marx JO, Pacharinsak C. Mouse anesthesia: the art and science. ILAR J. 2021;62(1-2):238-273. doi:10.1093/ilar/ilab016
Aarnes TK, Dent BT, Lakritz J, et al. Pharmacokinetics and pharmacodynamics of intramuscular dexmedetomidine in dogs. Am J Vet Res. 2023;84(4):ajvr.22.10.0184. doi:10.2460/ajvr.22.10.0184
Granholm M, McKusick BC, Westerholm FC, et al. Evaluation of the clinical efficacy and safety of dexmedetomidine or medetomidine in cats and their reversal with atipamezole. Vet Anaesth Analg. 2006;33:214-223.
Yamashita K, Yonezawa K, Izumisawa Y, Kotani T. Antagonistic effects of atipamezole on medetomidine-induced sedation in horses. J Vet Med Sci. 1996;58(10):1049-1052. doi:10.1292/jvms.58.10_1049
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Antisedan® NADA 141-033 approval letter. 1996. Retrieved August 7, 2023, from https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/562
Vainio O. Reversal of medetomidine-induced cardiovascular and respiratory changes with atipamezole in dogs. Vet Rec. 1990;127(18):447-450.
Mees L, Fidler J, Kreuzer M, Fu J, Pardue MT, García PS. Faster emergence behavior from ketamine/xylazine anesthesia with atipamezole versus yohimbine. PLoS ONE. 2018;13(10):e0199087. doi:10.1371/journal.pone.0199087
United States Department of Agriculture, U. States Department of Agriculture, Animal and Plant Health Inspection Service, A., and Plant Health Inspection Service. USDA animal care: Animal welfare act and animal welfare regulations. 2017.
National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. National Academies Press (US); 2011.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021.
Pertovaara A. Antinociception induced by á2-adrenoceptor agonists, with special emphasis on medetomidine studies. Prog Neurobiol. 1993;40:691-709.
Pan SY, Liu G, Lin JH, Jin YP. Efficacy and safety of dexmedetomidine premedication in balanced anesthesia: a systematic review and meta-analysis in dogs. Animals. 2021;11(11):3254. doi:10.3390/ani11113254
Waldridge BM, Lin HC, DeGraves FJ, Pugh DG. Sedative effects of medetomidine and its reversal by atipamezole in llamas. J Am Vet Med Assoc. 1997;211(12):1562-1565.
Haapalinna A, Viitamaa T, MacDonald E, et al. Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behavior in comparison with yohimbine. Naunyn Schmiedeberg's Arch Pharmacol. 1997;356(5):570-582. doi:10.1007/pl00005092
Zaretsky DV, Zaretskaia MV, DiMicco JA, Rusyniak DE. Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg. Neurosci Lett. 2015;606:215-219. doi:10.1016/j.neulet.2015.09.008
Zoetis and Orion Corporation. Antisedan (Atipamezole Hydrochloride). Dexmedetomidine and Medetomidine Reversing Agent For intramuscular use in dogs only; 2019.
Nguyen D, Abdul-Rasool I, Ward D, et al. Ventilatory effects of dexmedetomidine, atipamezole, and isoflurane in dogs. Anesthesiology. 1992;76:573-579. doi:10.1097/00000542-199204000-00014
Short CE, Bufalari A. Propofol anesthesia. Vet Clin North Am Small Anim Pract. 1999;29(3):747-778. doi:10.1016/S0195-5616(99)50059-4
Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370-380. doi:10.1111/cns.12099
Baker NJ, Schofield JC, Caswell MD, McLellan AD. Effects of early atipamezole reversal of medetomidine-ketamine anesthesia in mice. J Am Assoc Lab Anim Sci. 2011;50(6):916-920.